GRI Bio, Inc. Common Stock
$1.81
-$0.01 (-0.55%)
$1.75Day Range$1.85
Key Statistics
Market Cap
$3.96M
Shares Outstanding
2.2M
Primary Exchange
XNAS
Currency
USD
Type
CS
IPO Date
Apr 24, 2023
Round Lot
100
Locale
US
Trading Data
Day Open
$1.81
Day High
$1.85
Day Low
$1.75
Volume
48.0K
VWAP
$1.81
Prev Close
$1.82
Transactions
--
Acc. Volume
--
About GRI Bio, Inc. Common Stock
GRI Bio Inc is a clinical-stage biotech company focused on discovering, developing, and commercializing therapies targeting serious diseases associated with dysregulated immune responses that to inflammatory, fibrotic, and autoimmune disorders. GRI Bio's program, GRI-0621, is a small molecule RAR-beta and gamma dual agonist that inhibits the activity of human NKT I cells, returning the immune system to homeostasis. It is also an oral formulation of tazarotene, a synthetic RAR-beta and gamma selective agonist for the topical treatment of psoriasis and acne. The company's other product candidate GRI-0803 is a novel oral agonist of type 2 Natural Killer T (type 2 NKT) cells which can be a potential treatment for autoimmune disorders.
PHARMACEUTICAL PREPARATIONSSIC 28345 employees2223 AVENIDA DE LA PLAYA, LA JOLLA, CA, 92037(619) 400-1171IPO Apr 24, 2023US / STOCKSActiveWebsite
Identifiers
- CIK
- 0001824293
- Composite FIGI
- BBG00XZQMLV6
- Share Class FIGI
- BBG00XZQMLW5
- Ticker Root
- GRI
- SIC Code
- 2834
About GRI Bio, Inc. Common Stock (GRI) Stock
GRI Bio, Inc. Common Stock (GRI) closed the 2026-09-16 session at $1.81, down 0.55% versus the previous close (-0.01). The stock opened at $1.81 and traded between $1.75 and $1.85 during that session. Session trading volume was 48K shares. The volume-weighted average price (VWAP) is $1.81.
GRI Bio Inc is a clinical-stage biotech company focused on discovering, developing, and commercializing therapies targeting serious diseases associated with dysregulated immune responses that to inflammatory, fibrotic, and autoimmune disorders. GRI Bio's program, GRI-0621, is a small molecule RAR-beta and gamma dual agonist that inhibits the activity of human NKT I cells, returning the immune system to homeostasis. It is also an oral formulation of tazarotene, a synthetic RAR-beta and gamma selective agonist for the topical treatment of psoriasis and acne. The company's other product candidate GRI-0803 is a novel oral agonist of type 2 Natural Killer T (type 2 NKT) cells which can be a potential treatment for autoimmune disorders.
GRI Bio, Inc. Common Stock has a market capitalization of $4.0 million. The company operates in the PHARMACEUTICAL PREPARATIONS industry classification. GRI is listed on the XNAS exchange. The company employs approximately 5 people. GRI Bio, Inc. Common Stock is headquartered in LA JOLLA, CA. The recorded listing date is 2023-04-24.
On this page you can find market GRI stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the PHARMACEUTICAL PREPARATIONS sector.